Thermo Fisher Scientific Inc. $TMO Shares Sold by Diversify Advisory Services LLC

Diversify Advisory Services LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 34.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,054 shares of the medical research company’s stock after selling 1,065 shares during the period. Diversify Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $996,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Pinnacle Associates Ltd. lifted its position in Thermo Fisher Scientific by 2.3% during the third quarter. Pinnacle Associates Ltd. now owns 24,086 shares of the medical research company’s stock valued at $11,682,000 after purchasing an additional 534 shares during the period. Prevail Innovative Wealth Advisors LLC purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $236,000. B. Metzler seel. Sohn & Co. AG lifted its holdings in shares of Thermo Fisher Scientific by 0.5% in the 3rd quarter. B. Metzler seel. Sohn & Co. AG now owns 616,501 shares of the medical research company’s stock valued at $299,015,000 after buying an additional 2,776 shares during the period. Rathbones Group PLC boosted its stake in shares of Thermo Fisher Scientific by 4.1% in the third quarter. Rathbones Group PLC now owns 942,391 shares of the medical research company’s stock worth $457,078,000 after buying an additional 37,037 shares during the last quarter. Finally, Vinva Investment Management Ltd grew its holdings in Thermo Fisher Scientific by 21.9% during the third quarter. Vinva Investment Management Ltd now owns 32,256 shares of the medical research company’s stock worth $14,904,000 after acquiring an additional 5,803 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $495.98 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99. The firm has a market capitalization of $184.25 billion, a PE ratio of 27.96, a P/E/G ratio of 2.88 and a beta of 0.96. The business’s 50 day moving average price is $562.46 and its 200-day moving average price is $548.87.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.10 earnings per share. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be paid a $0.47 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is 9.70%.

Analyst Ratings Changes

A number of research analysts have issued reports on TMO shares. UBS Group reissued a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a report on Friday, January 30th. HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Monday, December 1st. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. The Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price objective for the company. Finally, Stifel Nicolaus increased their target price on shares of Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $633.68.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $541.20, for a total value of $216,480.00. Following the completion of the sale, the executive vice president directly owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. This represents a 1.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.